This Pivotal study will investigate the bioavailability in fasting women of 1 Tablet formulations containing Clotiazepam 5 mg.
The Pivotal study will be performed at a single site with 30 subjects. Participants will take 1 Tablet of the test product and reference product in 2 periods and 2 sequences (either test after reference or reference after test). There will be a washout of at least 7 days between each study period.

开始日期2020-03-11

申办/合作机构

Laboratorios Andrómaco SA

100 项与氯噻西泮相关的临床结果

登录后查看更多信息

100 项与氯噻西泮相关的转化医学

登录后查看更多信息

100 项与氯噻西泮相关的专利（医药）

登录后查看更多信息

项与氯噻西泮相关的文献（医药）

2023-09-01·Psychiatry and Clinical Neurosciences Reports

Clinical practice for unspecified anxiety disorder in primary care

Article

作者: Watanabe, Koichiro ; Aoki, Yumi ; Takeshima, Masahiro ; Inada, Ken ; Yoshida, Eriko ; Hori, Hikaru ; Sakurai, Hitoshi ; Kise, Morito ; Shimizu, Eiji ; Ie, Kenya ; Takaesu, Yoshikazu ; Yamada, Hisashi ; Inada, Yasushi ; Mishima, Kazuo ; Tsuboi, Takashi

AbstractAimClinicians face difficulties in making treatment decisions for unspecified anxiety disorder due to the absence of any treatment guidelines. The objective of this study was to investigate how familiar and how often primary care physicians use pharmacological and nonpharmacological approaches to manage the disorder.MethodsA survey was conducted among 117 primary care physicians in Japan who were asked to assess the familiarity of using each treatment option for unspecified anxiety disorder on a binary response scale (0 = “unfamiliar,” 1 = “familiar”) and the frequency on a nine‐point Likert scale (1 = “never used,” 9 = “frequently used”).ResultsWhile several benzodiazepine anxiolytics were familiar to primary care physicians, the frequencies of prescribing them, including alprazolam (4.6 ± 2.6), ethyl loflazepate (3.6 ± 2.4), and clotiazepam (3.5 ± 2.3), were low. In contrast, certain nonpharmacological options, including lifestyle changes (5.4 ± 2.3), coping strategies (5.1 ± 2.7), and psychoeducation for anxiety (5.1 ± 2.7), were more commonly utilized, but to a modest extent. When a benzodiazepine anxiolytic drug failed to be effective, primary care physicians selected the following management strategies to a relatively high degree: differential diagnosis (6.4 ± 2.4), referral to a specialist hospital (5.9 ± 2.5), lifestyle changes (5.2 ± 2.5), and switching to selective serotonin reuptake inhibitor (5.1 ± 2.4).ConclusionPrimary care physicians exercise caution when prescribing benzodiazepine anxiolytics for unspecified anxiety disorder. Nonpharmacological interventions and switching to SSRI are modestly employed as primary treatment options and alternatives to benzodiazepine anxiolytics. To ensure the safe and effective treatment of unspecified anxiety disorder in primary care, more information should be provided from field experts.

2023-07-01·Contact dermatitis

Localized delayed-type hypersensitivity of face and lips from alprazolam and cross-reactivity with other benzodiazepines.

作者: De Pasquale, Tiziana Maria Angela ; Buonomo, Alessandro ; Pucci, Stefano

Allergic reactions to benzodiazepines are relatively rare.Besides airborne (occupational) allergic contact dermatitis, which has been frequently reported about, both immediate and delayed-type hypersensitivities have been described, the latter including, among others, fixed drug eruption, generalized reactions, and Stevens-Johnson′s syndrome.A 40-yr-old man was admitted to the allergy unit of the Civitanova Marche hospital with a history of two episodes of an itchy eczematous rash of the face and 1 episode of lip edema, both occurring after the oral intake of alprazolam.The patient had started treatment with alprazolam about 10 mo before the reactions started to occur.Patch tests with the oral liquid formulations of alprazolam (0.75 mg/mL), diazepam (5 mg/mL) delorazepam (1 mg/mL), lormetazepam (2.5 mg/mL), bromazepam (2.5 mg/mL), triazolam (0.375 mg/mL), clotiazepam (10 mg/mL) and lorazepam (2 mg/mL) were performed.Even if the clin. picture was not typical, clin. history and patch test results were suggestive of a delayed-type hypersensitivity to alprazolam, with eventually cross-reactivity to diazepam, delorazepam, lormetazepam ad bromazepam.In our case, patch tests showed a good neg. predictive value since the patients tolerated lorazepam, clotiazepam and midazolam which were patch-test neg.Delayed-type allergy to benzodiazepines should be taken in consideration when the clin. history is highly suggestive, even when the clin. picture is atypical.

2022-04-01·Prosthetics & Orthotics International4区 · 医学

Jumping stump phenomenon: a case report

4区 · 医学

Article

作者: Rombauts, Maarten ; Peers, Koen ; Duinslaeger, Eva ; Kiekens, Carlotte

Case description:The jumping stump phenomenon is a peripherally induced movement disorder that is due to peripheral nerve damage. We report on a very resistant case in which different treatment strategies were applied.Objectives:To inform physicians about this condition, its implications, and treatment options.Study design:Case report of a 52-year-old man with a transtibial amputation, experiencing very painful involuntary muscle contractions in the residual limb.Treatment and outcomes:Various drug treatments, including baclofen, diazepam, clonazepam, clotiazepam, pramipexole, and pregabalin, peroneal nerve block, prosthesis modifications, and physiotherapy were ineffective for our patient. Botulinum toxin A treatment showed temporary decrease of symptoms but was not repeated because of high cost for the patient and his fear of injections. In our case, tibial nerve neuroma had no ectopic trigger zone, so local treatment was not indicated. Surgical interventions, based on contraction location and muscle tension, were partially successful. Eventually, due to serious functional and psychological impact, a transfemoral amputation was performed, with complete resolution of symptoms but recurrence later that year. Relapse was correlated with recurrence of local residual limb pain.Conclusions:Treating this phenomenon remains challenging because pathophysiology is still not fully understood, and the available literature is limited. A multiprofessional and interdisciplinary treatment approach is recommended, and botulinum toxin treatment is promising.

100 项与氯噻西泮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01328	氯噻西泮	N05BA21	DB01559

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
焦虑症	日本	Mitsubishi Tanabe Pharma Corp.	1998-01-26
紧张症	日本	Mitsubishi Tanabe Pharma Corp.	1998-01-26
入睡和睡眠障碍	日本	Mitsubishi Tanabe Pharma Corp.	1998-01-26
自主神经紊乱	日本	Mitsubishi Tanabe Pharma Corp.	1988-05-31